[go: up one dir, main page]

WO2007031280A3 - Cell-permeable peptide inhibitors of the jnk signal transduction pathway - Google Patents

Cell-permeable peptide inhibitors of the jnk signal transduction pathway Download PDF

Info

Publication number
WO2007031280A3
WO2007031280A3 PCT/EP2006/008882 EP2006008882W WO2007031280A3 WO 2007031280 A3 WO2007031280 A3 WO 2007031280A3 EP 2006008882 W EP2006008882 W EP 2006008882W WO 2007031280 A3 WO2007031280 A3 WO 2007031280A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
signal transduction
transduction pathway
peptide inhibitors
permeable peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/008882
Other languages
French (fr)
Other versions
WO2007031280A2 (en
Inventor
Christophe Bonny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xigen SA
Original Assignee
Xigen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA200804223A priority Critical patent/UA98101C2/en
Priority to HK08112945.3A priority patent/HK1118841B/en
Priority to CN2006800333412A priority patent/CN101263157B/en
Priority to MEP-2014-123A priority patent/ME02000B/en
Priority to EP06792004A priority patent/EP1928903B1/en
Priority to AU2006291541A priority patent/AU2006291541B2/en
Priority to KR1020087006094A priority patent/KR101305533B1/en
Priority to EA200800680A priority patent/EA014330B1/en
Priority to SI200631345T priority patent/SI1928903T1/en
Priority to DK06792004.1T priority patent/DK1928903T3/en
Priority to RS20120310A priority patent/RS52379B/en
Priority to CA2621337A priority patent/CA2621337C/en
Priority to ES06792004T priority patent/ES2388076T3/en
Priority to PL06792004T priority patent/PL1928903T3/en
Priority to US12/066,657 priority patent/US8748395B2/en
Application filed by Xigen SA filed Critical Xigen SA
Priority to HRP20120598TT priority patent/HRP20120598T1/en
Priority to JP2008530405A priority patent/JP5386169B2/en
Priority to BRPI0616824A priority patent/BRPI0616824B8/en
Publication of WO2007031280A2 publication Critical patent/WO2007031280A2/en
Publication of WO2007031280A3 publication Critical patent/WO2007031280A3/en
Priority to IL189133A priority patent/IL189133A/en
Anticipated expiration legal-status Critical
Priority to NO20081664A priority patent/NO342272B1/en
Priority to US14/144,938 priority patent/US9290538B2/en
Priority to IL237984A priority patent/IL237984A0/en
Priority to US15/045,058 priority patent/US20160264630A1/en
Priority to US15/628,771 priority patent/US20170320917A1/en
Priority to US16/525,234 priority patent/US20200062805A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)

Abstract

The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling.
PCT/EP2006/008882 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway Ceased WO2007031280A2 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
US12/066,657 US8748395B2 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CN2006800333412A CN101263157B (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
MEP-2014-123A ME02000B (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EP06792004A EP1928903B1 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
AU2006291541A AU2006291541B2 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
KR1020087006094A KR101305533B1 (en) 2005-09-12 2006-09-12 Cell―permeable peptide inhibitors of the jnk signal transduction pathway
EA200800680A EA014330B1 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
SI200631345T SI1928903T1 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
DK06792004.1T DK1928903T3 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
RS20120310A RS52379B (en) 2005-09-12 2006-09-12 PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUTION ROUTE PERMEABLE TO THE CELL
CA2621337A CA2621337C (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
ES06792004T ES2388076T3 (en) 2005-09-12 2006-09-12 Peptide cell permeability inhibitors of the JNK signal transduction pathway
PL06792004T PL1928903T3 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
UAA200804223A UA98101C2 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
HRP20120598TT HRP20120598T1 (en) 2005-09-12 2006-09-12 STANICALLY PERMEABLE PEPTIDE INHIBITORS OF JNK SIGNAL TRANSDUCTION ROUTE
HK08112945.3A HK1118841B (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
JP2008530405A JP5386169B2 (en) 2005-09-12 2006-09-12 Cell penetrating peptide inhibitors of JNK signaling pathway
BRPI0616824A BRPI0616824B8 (en) 2005-09-12 2006-09-12 chimeric peptide, its use, pharmaceutical composition comprising it, and kit
IL189133A IL189133A (en) 2005-09-12 2008-01-30 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
NO20081664A NO342272B1 (en) 2005-09-12 2008-04-04 JNK inhibitor sequence, chimeric peptide, pharmaceutical composition and their use.
US14/144,938 US9290538B2 (en) 2005-09-12 2013-12-31 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
IL237984A IL237984A0 (en) 2005-09-12 2015-03-26 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US15/045,058 US20160264630A1 (en) 2005-09-12 2016-02-16 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
US15/628,771 US20170320917A1 (en) 2005-09-12 2017-06-21 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
US16/525,234 US20200062805A1 (en) 2005-09-12 2019-07-29 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/009782 WO2007031098A1 (en) 2005-09-12 2005-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EPPCT/EP2005/009782 2005-09-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/066,657 A-371-Of-International US8748395B2 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US14/144,938 Division US9290538B2 (en) 2005-09-12 2013-12-31 Cell-permeable peptide inhibitors of the JNK signal transduction pathway

Publications (2)

Publication Number Publication Date
WO2007031280A2 WO2007031280A2 (en) 2007-03-22
WO2007031280A3 true WO2007031280A3 (en) 2007-05-24

Family

ID=35686501

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/009782 Ceased WO2007031098A1 (en) 2005-09-12 2005-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
PCT/EP2006/008882 Ceased WO2007031280A2 (en) 2005-09-12 2006-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009782 Ceased WO2007031098A1 (en) 2005-09-12 2005-09-12 Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Country Status (25)

Country Link
US (5) US8748395B2 (en)
EP (3) EP2418217B1 (en)
JP (3) JP5386169B2 (en)
KR (1) KR101305533B1 (en)
CN (1) CN101263157B (en)
AU (1) AU2006291541B2 (en)
BR (1) BRPI0616824B8 (en)
CA (1) CA2621337C (en)
CY (2) CY1112924T1 (en)
DK (2) DK2418217T3 (en)
EA (1) EA014330B1 (en)
ES (2) ES2567708T3 (en)
HK (1) HK1223948A1 (en)
HR (2) HRP20120598T1 (en)
HU (1) HUE029132T2 (en)
IL (2) IL189133A (en)
ME (2) ME02426B (en)
NO (1) NO342272B1 (en)
PL (2) PL1928903T3 (en)
PT (1) PT1928903E (en)
RS (2) RS54701B1 (en)
SI (2) SI2418217T1 (en)
UA (1) UA98101C2 (en)
WO (2) WO2007031098A1 (en)
ZA (1) ZA200800848B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569447B2 (en) 1999-10-12 2013-10-29 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8748395B2 (en) 2005-09-12 2014-06-10 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US9006185B2 (en) 2008-05-30 2015-04-14 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9180159B2 (en) 2008-05-30 2015-11-10 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
US9205048B2 (en) 2008-07-21 2015-12-08 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US9427472B2 (en) 2008-07-21 2016-08-30 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP2074138A4 (en) 2006-09-19 2009-12-30 Phylogica Ltd Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
WO2008154700A1 (en) * 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
GB2461961A (en) * 2008-07-14 2010-01-27 Otonomy Inc Sterile anti-apoptotic agent for treatment of ear diseases
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
AU2009274229B2 (en) 2008-07-21 2013-08-22 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
JP2012506436A (en) 2008-10-22 2012-03-15 ハウス イアー インスティトゥート Treatment and / or prevention of inner ear diseases by modulation of metabotropic glutamate receptors
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
KR20120022721A (en) 2009-03-30 2012-03-12 산텐 세이야꾸 가부시키가이샤 Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase)-inhibitory peptide, and use of the peptide
WO2010151638A1 (en) * 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
WO2011160653A1 (en) * 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2012344299A1 (en) * 2011-11-30 2014-05-29 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of dry eye syndrome
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015197098A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206426A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2016055160A2 (en) 2014-10-08 2016-04-14 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
JP2016523274A (en) * 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド Use of novel cell penetrating peptide inhibitors of the JNK signaling pathway to treat various diseases
US9926354B2 (en) 2014-01-09 2018-03-27 University Of South Florida Amyloid precursor protein (APP) based Ã#-secretase inhibitor peptides, and methods of use
EP3139744A4 (en) * 2014-04-23 2017-12-20 Auris Medical AG Methods and compositions for treating and preventing tinnitus
WO2015200768A2 (en) * 2014-06-26 2015-12-30 Auris Medical Ag Pharmacologic treatments of menière's disease
EP3160989A2 (en) * 2014-06-26 2017-05-03 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US10190096B2 (en) 2014-12-18 2019-01-29 President And Fellows Of Harvard College Methods for generating stem cell-derived β cells and uses thereof
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
EP3411387A4 (en) 2016-02-03 2019-12-04 Kennesaw State University Research And Services Foundation Inc. SIGNAL MOLECULES USEFUL AS CELL PENETRATION AGENTS
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. GEL FORMULA FOR THE EAR FOR TREATING OTITIS EXTERNA
EP3618807A4 (en) * 2017-05-03 2021-01-20 Jian Zuo HEARING LOSS PREVENTION COMPOSITIONS AND METHODS
IT202000011176A1 (en) 2020-05-15 2021-11-15 Univ Degli Studi Milano JNK3 INHIBITOR PEPTIDES
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
IL305883A (en) 2021-03-18 2023-11-01 Seagen Inc Selective drug release from internalized conjugates of biologically active compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027268A2 (en) * 1999-10-12 2001-04-19 University Of Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195304B (en) 1981-12-22 1988-10-12 Anic Spa METHOD FOR THE PREPARATION OF GEM-DIAMINE N-MONOACYLATED DERIVATIVES
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IT1190389B (en) 1985-09-19 1988-02-16 Eniricerche Spa HEXOTEPTIDES WITH HYPOTENSIVE ACTIVITY
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IT1227907B (en) 1988-12-23 1991-05-14 Eniricerche S P A Milano Sclav PROCEDURE FOR THE SYNTHESIS OF RETRO-REVERSE AND NEW INTERMEDIATE PEPTIDES IN THIS PROCEDURE
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
AU1753892A (en) 1991-04-10 1992-11-17 General Hospital Corporation, The Mammalian gap-43 compositions and methods of use
US5994108A (en) 1991-11-05 1999-11-30 Board Of Regents, The University Of Texas System Mutant TAR virus and transdominant tat mutants as pharmacological agents
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
JPH07505283A (en) 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン DNA transporter system and method of use
WO1993019768A1 (en) 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
EP0673385A4 (en) 1992-08-13 1995-11-29 Gen Hospital Corp HUMAN GAP-43 COMPOSITIONS AND METHODS FOR THEIR USE.
DK0656950T3 (en) 1992-08-21 1999-07-19 Biogen Inc TAT-derived transport polypeptides
AU667578B2 (en) 1992-08-27 1996-03-28 Deakin Research Limited Retro-, inverso-, and retro-inverso synthetic peptide analogues
US5545551A (en) 1992-08-28 1996-08-13 Mt. Sinai School Of Medicine Of The City University Of New York Cloning and expression of pur protein
JP3789930B2 (en) 1992-10-09 2006-06-28 アドバンスド ティシュー サイエンシズ，インコーポレーテッド Liver spare cells
EP0693939A1 (en) 1993-04-14 1996-01-31 Roche Diagnostics GmbH Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
CA2153480A1 (en) 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
JPH10508205A (en) 1995-04-25 1998-08-18 バクスター インターナショナル インコーポレイテッド Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet of Langerhans cells
CN1208438A (en) 1995-07-28 1999-02-17 玛丽·柯里癌症治疗中心 Transport proteins and their uses
WO1997010836A1 (en) 1995-09-21 1997-03-27 Innapharma, Inc. Peptides and peptidomimetics inhibiting the oncogenic action of p21 ras
IE80466B1 (en) 1995-11-10 1998-07-29 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US6187817B1 (en) 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
AU7410998A (en) 1996-11-26 1998-06-22 Johns Hopkins University, The Ligand detection system and methods of use thereof
US5989814A (en) 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
US5880261A (en) 1997-04-03 1999-03-09 Waeber; Gerard Transcription factor Islet-Brain 1 (IB1)
AU6972798A (en) 1997-04-18 1998-11-13 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
JP4129298B2 (en) 1997-05-15 2008-08-06 サイトジェン コーポレーション Random peptides that bind to the gastrointestinal tract (GIT) transport receptor and related methods
US20040152084A1 (en) 2003-01-31 2004-08-05 Slattum Paul M. Compounds and processes for single-pot attachment of a label to nucleic acid
BR9809138A (en) 1997-05-21 2001-08-28 Trustees For The Leland Stanfo Conjugate and method to increase the transport of a selected compound across a biological membrane
FR2767323B1 (en) 1997-08-12 2001-01-05 Synt Em LINEAR PEPTIDES DERIVED FROM ANTIBIOTIC PEPTIDES, THEIR PREPARATION AND THEIR USE FOR VECTORIZING ACTIVE SUBSTANCES
EP0897002A3 (en) 1997-08-14 2001-10-04 Smithkline Beecham Plc U62317, a protein having a JNK-binding domain
AU9402898A (en) 1997-09-26 1999-04-23 Washington University Cell death agonists
US6420031B1 (en) 1997-11-03 2002-07-16 The Trustees Of Princeton University Highly transparent non-metallic cathodes
PL340412A1 (en) 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
US6270956B1 (en) 1997-12-11 2001-08-07 The Salk Institute For Biological Studies Transcriptional coactivator that interacts with Tat protein and regulates its binding to TAR RNA, methods for modulating Tat transactivation, and uses therefor
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
JP2002513008A (en) 1998-04-29 2002-05-08 ジョージタウン ユニヴァーシティー Methods for identifying and using HLA-binding compounds as HLA-agonists and antagonists
CA2327354A1 (en) 1998-05-13 1999-11-18 Incyte Pharmaceuticals, Inc. Human apoptosis associated proteins
WO1999058561A1 (en) 1998-05-14 1999-11-18 Pasteur Merieux Serums & Vaccins Hepatitis c virus mimotopes
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
CA2331384A1 (en) 1998-06-18 1999-12-23 Dnavec Research Inc. Nucleic acid transfer phage
JP2002518521A (en) 1998-06-20 2002-06-25 ワシントン・ユニバーシティ Membrane permeable peptide complexes for medical image analysis, diagnosis and therapy
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
DE69936322T2 (en) 1998-08-28 2008-02-21 Amylin Pharmaceuticals, Inc., San Diego Polyamide chains of exact length and their conjugates with proteins
HK1040053B (en) 1998-09-25 2007-09-21 Cephalon, Inc. Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons
US6656474B1 (en) 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
CA2373814A1 (en) 1999-05-28 2001-02-15 Apoptosis Technology, Inc. Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
DK1102785T3 (en) 1999-06-07 2013-05-13 Arrowhead Res Corp Compositions for drug delivery using pH-sensitive molecules
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
EP2269654A3 (en) 1999-08-24 2011-04-13 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
EP1210362A2 (en) 1999-09-01 2002-06-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses
US20030108539A1 (en) 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CN100475953C (en) 1999-12-06 2009-04-08 通用医疗公司 pancreatic stem cells
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
CA2425610A1 (en) 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
DK1333846T3 (en) 2000-10-17 2012-08-06 Diatranz Otsuka Ltd Preparation and xenotransplantation of porcine islands
US20030077826A1 (en) 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
WO2002062792A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
AU2002240312A1 (en) 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
CA2437983C (en) 2001-02-16 2011-10-25 Cellgate, Inc. Transporters comprising spaced arginine moieties
US6653443B2 (en) 2001-04-06 2003-11-25 Thomas Jefferson University Multimerization of HIV-1 Vif protein as a therapeutic target
DE10117281A1 (en) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptide for the diagnosis and therapy of Alzheimer's dementia
US20060216706A1 (en) 2001-07-17 2006-09-28 Tang Y T Proteins associated with cell growth, differentiation, and death
WO2004045535A2 (en) 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
JP2005525096A (en) 2002-01-09 2005-08-25 ユニバーシティ オブ ローザンヌ Cell penetrating peptide inhibitors of the JNK signaling pathway
JP2005533748A (en) 2002-03-08 2005-11-10 シグナル ファーマシューティカルズ，インコーポレイテッド Combination therapies to treat, prevent, or manage proliferative disorders and cancer
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
EP1590363A4 (en) 2002-09-09 2006-11-02 Dana Farber Cancer Inst Inc PEPTIDES BH3 AND METHODS OF USE
AU2003278727A1 (en) 2002-09-20 2004-04-08 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
ES2279849T3 (en) 2002-10-11 2007-09-01 Imvision Gmbh TRANSPORT MOLECULES OF MODULAR ANTIGENS (MAT MOLECULES) FOR THE MODULATION OF IMMUNE REACTIONS, CONSTRUCTS, PROCEDURES AND USES OF THE SAME.
AU2003286611A1 (en) 2002-10-24 2004-05-13 Sangstat Medical Corporation Cytomodulating peptides and methods for treating neurological disorders
NZ540546A (en) 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20050019366A1 (en) 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
EP1599475A2 (en) 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
WO2004092339A2 (en) 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
ES2500921T3 (en) 2003-04-29 2014-10-01 Sarepta Therapeutics, Inc. Compositions to enhance the transport and antisense efficacy of nucleic acid analogs in cells
EP1732581A4 (en) 2003-06-20 2008-06-04 Univ California San Diego POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES
KR100685345B1 (en) 2004-03-27 2007-02-22 학교법인조선대학교 Cell Death Inducing Peptides
US20080039377A1 (en) 2004-04-08 2008-02-14 Applied Research Systems Ars Holding N.V. Composition Comprising a Jnk Inhibitor and Cyclosporin
WO2006021458A2 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
EP1656951A1 (en) 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
US20070015779A1 (en) 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
CN101208333A (en) 2005-04-29 2008-06-25 细胞基因公司 Solid forms of 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene
US20070003531A1 (en) 2005-06-30 2007-01-04 University Of Connecticut Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2008006046A1 (en) 2006-07-06 2008-01-10 Case Western Reserve University Ceramide composition and use thereof in treatment of ocular diseases
US20080051410A1 (en) 2006-08-02 2008-02-28 Northwestern University Protein Kinase Targeted Therapeutics
ES2378577T3 (en) 2006-09-08 2012-04-16 F. Hoffmann-La Roche Ag Benzotriazole as kinase modulators
EP2074138A4 (en) * 2006-09-19 2009-12-30 Phylogica Ltd Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
GB0702259D0 (en) 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-azaindole derivatives
DK2285364T3 (en) 2008-05-07 2015-02-16 Univ California THERAPEUTIC REGENERATING AND ENRICHMENT OF the ocular surface GREASE
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010065850A2 (en) 2008-12-04 2010-06-10 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
KR20120022721A (en) 2009-03-30 2012-03-12 산텐 세이야꾸 가부시키가이샤 Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase)-inhibitory peptide, and use of the peptide
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
PL2627346T3 (en) 2010-10-14 2016-11-30 Cell-permeable peptide inhibitors of the jnk signal transduction pathway for use in the treatment of uveitis
US8471027B2 (en) 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206426A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027268A2 (en) * 1999-10-12 2001-04-19 University Of Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARR R K ET AL: "IDENTIFICATION OF THE CRITICAL FEATURES OF A SMALL PEPTIDE INHIBITOR OF JNK ACTIVITY", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC.,, US, vol. 277, no. 13, 29 March 2002 (2002-03-29), pages 10987 - 10997, XP001155759, ISSN: 0021-9258 *
BONNY C ET AL: "Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death", DIABETES, NEW YORK, NY, US, vol. 50, no. 1, January 2001 (2001-01-01), pages 77 - 82, XP002274267, ISSN: 0012-1797 *
BONNY CHRISTOPHE ET AL: "Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases.", REVIEWS IN THE NEUROSCIENCES. 2005, vol. 16, no. 1, 2005, pages 57 - 67, XP009061133, ISSN: 0334-1763 *
BORSELLO TIZIANA ET AL: "A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia.", NATURE MEDICINE. SEP 2003, vol. 9, no. 9, September 2003 (2003-09-01), pages 1180 - 1186, XP002366119, ISSN: 1078-8956 *
BORSELLO TIZIANA ET AL: "Use of cell-permeable peptides to prevent neuronal degeneration.", TRENDS IN MOLECULAR MEDICINE. MAY 2004, vol. 10, no. 5, May 2004 (2004-05-01), pages 239 - 244, XP002366120, ISSN: 1471-4914 *
DATABASE UniProt 28 February 2003 (2003-02-28), XP002366175, retrieved from EBI Database accession no. Q9WVI9 *
VIVES E ET AL: "A TRUNCATED HIV-1 TAT PROTEIN BASIC DOMAIN RAPIDLY TRANSLOCATES THROUGH THE PLASMA MEMBRANE AND ACCUMULATES IN THE CELL NUCLEUS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 272, no. 25, 1997, pages 16010 - 16017, XP002931299, ISSN: 0021-9258 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569447B2 (en) 1999-10-12 2013-10-29 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8748395B2 (en) 2005-09-12 2014-06-10 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US9290538B2 (en) 2005-09-12 2016-03-22 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US9006185B2 (en) 2008-05-30 2015-04-14 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
US9180159B2 (en) 2008-05-30 2015-11-10 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
US9205048B2 (en) 2008-07-21 2015-12-08 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US9233068B2 (en) 2008-07-21 2016-01-12 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders
US9427472B2 (en) 2008-07-21 2016-08-30 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders

Also Published As

Publication number Publication date
KR20080052586A (en) 2008-06-11
BRPI0616824B1 (en) 2020-10-27
NO20081664L (en) 2008-04-04
RS52379B (en) 2012-12-31
EA200800680A1 (en) 2008-12-30
ES2567708T3 (en) 2016-04-26
JP2015034171A (en) 2015-02-19
CA2621337C (en) 2014-09-23
ZA200800848B (en) 2009-05-27
US20200062805A1 (en) 2020-02-27
JP2009507502A (en) 2009-02-26
KR101305533B1 (en) 2013-09-06
CN101263157A (en) 2008-09-10
ME02426B (en) 2016-09-20
US20140200187A1 (en) 2014-07-17
HK1163712A1 (en) 2012-09-14
RS54701B1 (en) 2016-08-31
PL2418217T3 (en) 2017-03-31
HK1223948A1 (en) 2017-08-11
CY1117351T1 (en) 2017-04-26
BRPI0616824B8 (en) 2021-05-25
EP3012266A1 (en) 2016-04-27
PT1928903E (en) 2012-07-02
WO2007031098A1 (en) 2007-03-22
EP2418217B1 (en) 2016-01-27
HRP20160379T1 (en) 2016-05-20
DK2418217T3 (en) 2016-03-21
DK1928903T3 (en) 2012-08-20
SI1928903T1 (en) 2012-09-28
AU2006291541B2 (en) 2012-04-12
ME02000B (en) 2015-05-20
IL237984A0 (en) 2015-05-31
US20160264630A1 (en) 2016-09-15
US20170320917A1 (en) 2017-11-09
HRP20120598T1 (en) 2012-08-31
US9290538B2 (en) 2016-03-22
AU2006291541A1 (en) 2007-03-22
JP5727393B2 (en) 2015-06-03
US8748395B2 (en) 2014-06-10
WO2007031280A2 (en) 2007-03-22
CY1112924T1 (en) 2016-04-13
ES2388076T3 (en) 2012-10-08
JP5386169B2 (en) 2014-01-15
JP2012095657A (en) 2012-05-24
IL189133A0 (en) 2008-08-07
CN101263157B (en) 2012-11-07
UA98101C2 (en) 2012-04-25
PL1928903T3 (en) 2012-10-31
IL189133A (en) 2015-04-30
EP1928903A2 (en) 2008-06-11
CA2621337A1 (en) 2007-03-22
US20090305968A1 (en) 2009-12-10
HK1118841A1 (en) 2009-02-20
SI2418217T1 (en) 2016-06-30
EP1928903B1 (en) 2012-05-30
EP2418217A1 (en) 2012-02-15
EA014330B1 (en) 2010-10-29
HUE029132T2 (en) 2017-02-28
PL2418217T4 (en) 2017-11-30
BRPI0616824A2 (en) 2011-07-05
NO342272B1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
WO2007031280A3 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
MX2014006399A (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome.
WO2014206563A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
PT2491942E (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various cardiovascular diseases
WO2005047511A3 (en) Bacterial expression of protease inhibitors and variants thereof
WO2003057725A3 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2005005462A3 (en) Blys antagonists and uses thereof
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
WO2005007818A3 (en) Exo-specific amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009068627A3 (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2009047992A1 (en) Udp-glucuronyl transferase and polynucleotide encoding the same
ATE497540T1 (en) TRANSPOSON SYSTEM FOR TARGETED INTEGRATION
WO2006054262A3 (en) Use of phage display technique for identifying peptides capable of binding progenitor/stem cells, peptides thereby obtained and uses thereof
WO2015197194A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2008112543A3 (en) Rat, rabbit, and cynomolgus monkey il-21 and il-22 nucleotide and polypeptide sequences
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
WO2008138001A3 (en) Synthetic peptides and peptide mimetics
WO2007124486A3 (en) Bmp4 inhibitors
WO2009135953A3 (en) Amino acid sequences directed against integrins and uses thereof
WO2007045019A3 (en) Polyoleosins
WO2016055160A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2013263786B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006792004

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 495/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 189133

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006291541

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2621337

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/003150

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200680033341.2

Country of ref document: CN

Ref document number: 2008530405

Country of ref document: JP

Ref document number: 1020087006094

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200800680

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2006291541

Country of ref document: AU

Date of ref document: 20060912

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006291541

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: A200804223

Country of ref document: UA

WWP Wipo information: published in national office

Ref document number: 2006792004

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12066657

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0616824

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080312

WWE Wipo information: entry into national phase

Ref document number: P-2012/0310

Country of ref document: RS

WWE Wipo information: entry into national phase

Ref document number: 237984

Country of ref document: IL